Protease-activated receptor 1 inhibition by SCH79797 attenuates left ventricular remodeling and profibrotic activities of cardiac fibroblasts

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 5, 2013, Pages 460-475

  Sonin, Dmitry L ^a,b   Wakatsuki, Tetsuro ^c   Routhu, Kasi V ^a   Harmann, Leanne M ^a   Petersen, Matthew ^d   Meyer, Jennifer ^a   Strande, Jennifer L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE   (Russian Federation)

^c InvivoSciences LLC   (United States)

^d Northeast Wisconsin Technical College   (United States)

Author keywords

3D cell culture; cardiac fibrosis; ischemia reperfusion; protease activated receptor 1; remodeling; thrombin receptor antagonist

Indexed keywords

1 AMINO 3 CYCLOPROPYLAMINO 7 (4 ISOPROPYLBENZYL) 7H PYRROLO[3,2 F]QUINAZOLINE; ALPHA SMOOTH MUSCLE ACTIN; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROCOLLAGEN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CELL ACTIVITY; CELL TRANSFORMATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; IN VITRO STUDY; MALE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY;

3D CELL CULTURE; CARDIAC FIBROSIS; ISCHEMIA-REPERFUSION; PROTEASE-ACTIVATED RECEPTOR 1; REMODELING; THROMBIN RECEPTOR ANTAGONIST;

ANIMALS; DISEASE MODELS, ANIMAL; FIBROBLASTS; FIBROSIS; IMAGING, THREE-DIMENSIONAL; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PHOSPHORYLATION; PYRROLES; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PAR-1; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR REMODELING;

EID: 84882278338     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413485434     Document Type: Article

References (39)

1. Floyd KC, Yarzebski J, Spencer FA, et al. A 30-year perspective (1975-2005) into the changing landscape of patients hospitalized with initial acute myocardial infarction: Worcester heart attack study. Circ Cardiovasc Qual Outcomes. 2009 ; 2 (2). 88-95
2. Roger VL. The heart failure epidemic. Int J Environ Res Public Health. 2010 ; 7 (4). 1807-1830
3. Park D, McManus D, Darling C, et al. Recent trends in the characteristics and prognosis of patients hospitalized with acute heart failure. Clin Epidemiol. 2011 ; 3: 295-303
4. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010 ; 7 (1). 30-37
5. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002 ; 53 (1). 31-47
6. Kuwahara F, Kai H, Tokuda K, et al. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation?. Hypertension. 2004 ; 43 (4). 739-745
7. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002 ; 3 (5). 349-363
8. Snead AN, Insel PA. Defining the cellular repertoire of gpcrs identifies a profibrotic role for the most highly expressed receptor, protease-activated receptor 1, in cardiac fibroblasts. Faseb J. 2012 ; 26 (11). 4540-4547
9. Sabri A, Short J, Guo J, Steinberg SF. Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct par-1 signaling pathways in cardiac fibroblasts and cardiomyocytes. Circ Res. 2002 ; 91 (6). 532-539
10. Deng X, Mercer PF, Scotton CJ, Gilchrist A, Chambers RC. Thrombin induces fibroblast ccl2/je production and release via coupling of par1 to g{alpha}q and cooperation between erk1/2 and rho kinase signaling pathways. Mol Biol Cell. 2008 ; 19 (6). 2520-2533
11. Moshal KS, Tyagi N, Henderson B, Ovechkin AV, Tyagi SC. Protease-activated receptor and endothelial-myocyte uncoupling in chronic heart failure. Am J Physiol Heart Circ Physiol. 2005 ; 288 (6). H2770 - H2777
12. Moshal KS, Tyagi N, Moss V, et al. Early induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure. J Cell Mol Med. 2005 ; 9 (3). 704-713
13. Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE. Sch 79797, a selective par1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res Cardiol. 2007 ; 102 (4). 350-358
14. Pawlinski R, Tencati M, Hampton CR, et al. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation. 2007 ; 116 (20). 2298-2306
15. Jaffre F, Friedman AE, Hu Z, Mackman N, Blaxall BC. Beta-adrenergic receptor stimulation transactivates protease-activated receptor 1 via mmp-13 in cardiac cells. Circulation. 2012 ; 125 (24). 2993-3003
16. Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE. Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling. J Pharmacol Exp Ther. 2008 ; 324 (3). 1045-1054
17. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003 ; 111 (8). 1201-1209
18. Jasmin JF, Calderone A, Leung TK, Villeneuve L, Dupuis J. Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan. Cardiovasc Res. 2003 ; 58 (3). 621-631
19. Seidman JG. In Situ hybridization and immunohistochemistry. Current Protocols in Molecular Biology. 2008 ; 82: 14.0.1-14.0.2
20. Whittaker P, Kloner RA, Boughner DR, Pickering JG. Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol. 1994 ; 89 (5). 397-410
21. Sun Y, Zhang JQ, Zhang J, Lamparter S. Cardiac remodeling by fibrous tissue after infarction in rats. J Lab Clin Med. 2000 ; 135 (4). 316-323
22. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (vegf) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004 ; 165 (1). 35-52
23. Migrino R, Zhu X, Morker M, Brahmbhatt T, Bright M, Zhao M. Myocardial dysfunction in the periinfarct and remote regions following anterior infarction in rats quantified by 2d radial strain echocardiography: an observational cohort study. Cardiovasc Ultrasound. 2008 ; 6: 17
24. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986 ; 57 (6). 450-458
25. Zhang H, Pi R, Li R, et al. Pparbeta/delta activation inhibits angiotensin ii-induced collagen type i expression in rat cardiac fibroblasts. Arch Biochem Biophys. 2007 ; 460 (1). 25-32
26. Marquez JP, Legant W, Lam V, Cayemberg A, Elson E, Wakatsuki T. High-throughput measurements of hydrogel tissue construct mechanics. Tissue Eng Part C Methods. 2009 ; 15 (2). 181-190
27. Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Graziano M. Inhibition of cellular action of thrombin by n3-cyclopropyl-7-[[4-(1-methylethyl)phenyl] methyl]-7h-pyrrolo[3, 2-f]quinazoline-1,3-diamine (sch 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol. 2000 ; 60 (10). 1425-1434
28. Emmert DA, Fee JA, Goeckeler ZM, et al. Rho-kinase-mediated ca2+-independent contraction in rat embryo fibroblasts. Am J Physiol Cell Physiol. 2004 ; 286 (1). C8 - C21
29. Bujak M, Ren G, Kweon HJ, et al. Essential role of smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation. 2007 ; 116 (19). 2127-2138
30. Dugina V, Fontao L, Chaponnier C, Vasiliev J, Gabbiani G. Focal adhesion features during myofibroblastic differentiation are controlled by intracellular and extracellular factors. J Cell Sci. 2001 ; 114 (pt 18). 3285-3296
31. Snead AN, Insel PA. Identification of new g protein-coupled receptor (gpcr) target(s) for the regulation of cardiac fibrosis. FASEB J. 2010 ; 24: 712-769
32. McLaughlin JN, Shen L, Holinstat M, Brooks JD, Dibenedetto E, Hamm HE. Functional selectivity of g protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. J Biol Chem. 2005 ; 280 (26). 25048-25059
33. Blackhart BD, Ruslim-Litrus L, Lu CC, et al. Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. Mol Pharmacol. 2000 ; 58 (6). 1178-1187
34. Erlich JH, Boyle EM, Labriola J, et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol. 2000 ; 157 (6). 1849-1862
35. Trivedi V, Boire A, Tchernychev B, et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating par1 at a cryptic ligand site. Cell. 2009 ; 137 (2). 332-343
36. Di Serio C, Pellerito S, Duarte M, et al. Protease-activated receptor 1-selective antagonist sch79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism. Basic Clin Pharmacol Toxicol. 2007 ; 101 (1). 63-69
37. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. New England Journal of Medicine. 2012 ; 366: 1404-1413
38. Wiviott SD, Flather MD, O'Donoghue ML, et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial.. 2011 ; 123: 1854-1863
39. Dallas, TX: American Heart Association ; 2005.